Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

2.

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.

3.

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.

4.

Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01400-16. doi: 10.1128/AAC.01400-16. Print 2017 Mar.

5.

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

van Altena R, Akkerman OW, Alffenaar JC, Kerstjens HA, Magis-Escurra C, Boeree MJ, van Soolingen D, de Lange WC, Bolhuis MS, Hoefsloot W, de Vries G, van der Werf TS.

Eur Respir J. 2016 Dec;48(6):1800-1802. doi: 10.1183/13993003.01208-2016. Epub 2016 Oct 6. No abstract available.

6.

Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.

Sturkenboom MG, Akkerman OW, van Altena R, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1237-1239. doi: 10.1183/13993003.00986-2016. Epub 2016 Aug 4. No abstract available.

7.

Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis.

Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

PLoS One. 2016 Mar 29;11(3):e0151724. doi: 10.1371/journal.pone.0151724. eCollection 2016.

8.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
9.

Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.

van Rijn SP, van Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1229-34. doi: 10.1183/13993003.01654-2015. Epub 2016 Jan 7.

10.

Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.

Dijkstra JA, van Altena R, Akkerman OW, de Lange WC, Proost JH, van der Werf TS, Kosterink JG, Alffenaar JW.

Int J Antimicrob Agents. 2015 Sep;46(3):332-7. doi: 10.1016/j.ijantimicag.2015.06.008. Epub 2015 Jul 15.

PMID:
26228464
11.

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.

12.

Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.

van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, van Soolingen D, Boeree MJ, van der Werf TS.

Int J Tuberc Lung Dis. 2015 Apr;19(4):406-12. doi: 10.5588/ijtld.14.0838.

PMID:
25859995
13.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB.

Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.

14.

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.

Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE.

Int J Antimicrob Agents. 2014 Sep;44(3):229-34. doi: 10.1016/j.ijantimicag.2014.04.019. Epub 2014 Jun 9.

PMID:
24985091
15.

Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response.

Akkerman OW, van Altena R, Bolhuis MS, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2014;58(1):628. doi: 10.1128/AAC.01535-13. No abstract available.

16.

Drug concentration in lung tissue in multidrug-resistant tuberculosis.

Akkerman OW, van Altena R, Klinkenberg T, Brouwers AH, Bongaerts AH, van der Werf TS, Alffenaar JW.

Eur Respir J. 2013 Dec;42(6):1750-2. doi: 10.1183/09031936.00047413. No abstract available.

17.

Trimethoprim/sulfamethoxazole susceptibility of Mycobacterium tuberculosis.

Alsaad N, van der Laan T, van Altena R, Wilting KR, van der Werf TS, Stienstra Y, van Soolingen D, Alffenaar JW.

Int J Antimicrob Agents. 2013 Nov;42(5):472-4. doi: 10.1016/j.ijantimicag.2013.07.011. Epub 2013 Aug 23. No abstract available.

PMID:
24035198
18.

Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis.

Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2014 Mar;43(3):884-97. doi: 10.1183/09031936.00113713. Epub 2013 Aug 29. Review.

19.

Rifampicin and moxifloxacin for tuberculous meningitis.

Akkerman O, Pranger A, van Altena R, van der Werf T, Alffenaar JW.

Lancet Infect Dis. 2013 Jul;13(7):568-9. doi: 10.1016/S1473-3099(13)70101-4. No abstract available.

PMID:
23809221
20.

[Dysphagia in a young woman from Somalia].

Veldhuis S, van Altena R, van Steenwijk RP, Rauws EA, Eeftinck Schattenkerk JK.

Ned Tijdschr Geneeskd. 2013;157(22):A5673. Dutch.

PMID:
23714291
21.

Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.

Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2013 Aug;57(8):3676-80. doi: 10.1128/AAC.00558-13. Epub 2013 May 20.

22.

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients.

Bolhuis MS, van Altena R, van Soolingen D, de Lange WC, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2013 Dec;42(6):1614-21. doi: 10.1183/09031936.00001913. Epub 2013 Mar 21.

23.

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, D'Ambrosio L, Lange CG, Bauer M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

Eur Respir J. 2013 Jul;42(1):156-68. doi: 10.1183/09031936.00134712. Epub 2012 Oct 25.

24.

Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.

Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW.

Eur Respir J. 2013 Aug;42(2):504-12. doi: 10.1183/09031936.00114812. Epub 2012 Oct 25.

25.

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.

Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D; “The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB”.

Eur Respir J. 2013 Jul;42(1):169-179. doi: 10.1183/09031936.00136312. Epub 2012 Oct 11.

26.

Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB.

Eur Respir J. 2013 Jun;41(6):1386-92. doi: 10.1183/09031936.00124312. Epub 2012 Sep 20.

27.

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

PLoS Med. 2012;9(8):e1001300. Epub 2012 Aug 28.

28.

Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, Brouwers JR, Uges DR, Alffenaar JW.

Antimicrob Agents Chemother. 2012 Nov;56(11):5758-63. doi: 10.1128/AAC.01054-12. Epub 2012 Aug 27.

29.

Comment on: daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.

Bolhuis MS, van Altena R, Alffenaar JW.

J Antimicrob Chemother. 2012 Aug;67(8):2055-6; author reply 2056-7. doi: 10.1093/jac/dks154. Epub 2012 Apr 27. No abstract available.

PMID:
22544851
30.

Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection.

van Altena R, Duggirala S, Gröschel MI, van der Werf TS.

Curr Pharm Des. 2011;17(27):2853-62. Review.

PMID:
21834760
31.

Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis.

Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, Alffenaar JW.

Ther Drug Monit. 2011 Jun;33(3):350-4. doi: 10.1097/FTD.0b013e31821b793c.

PMID:
21544017
32.

Nutritional status and vitamin D3 during antimicrobial treatment.

Warmelink I, van Altena R, ten Hacken N, van der Werf T, van der Veer E.

Lancet. 2011 Apr 23;377(9775):1407-8; author reply 1408. doi: 10.1016/S0140-6736(11)60576-X. No abstract available.

PMID:
21515160
33.

Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.

Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2011 Oct;38(4):888-94. doi: 10.1183/09031936.00176610. Epub 2011 Feb 10.

34.

[Practice guideline prevention, diagnosis and treatment of tuberculosis in patients with an HIV infection].

van Leth F, Gebhart AC, van Altena R, Rijkeboer AA, Reuskens AM, van Gerven PJ.

Ned Tijdschr Geneeskd. 2010;154:A1225. Dutch.

PMID:
21262033
35.

Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.

Warmelink I, ten Hacken NH, van der Werf TS, van Altena R.

Br J Nutr. 2011 Feb;105(3):400-8. doi: 10.1017/S0007114510003636. Epub 2010 Sep 28.

PMID:
20875187
36.

Clarithromycin significantly increases linezolid serum concentrations.

Bolhuis MS, van Altena R, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2010 Dec;54(12):5418-9. doi: 10.1128/AAC.00757-10. Epub 2010 Sep 13. No abstract available.

37.

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.

Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, van Soolingen D, Kosterink JG, Uges DR, van der Werf TS.

Clin Pharmacokinet. 2010 Aug;49(8):559-65. doi: 10.2165/11532080-000000000-00000.

PMID:
20608757
38.

Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.

Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH.

Ther Drug Monit. 2010 Feb;32(1):97-101. doi: 10.1097/FTD.0b013e3181cc6d6f.

PMID:
20042919
39.

Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis.

Alffenaar JW, van Altena R, Bökkerink HJ, Luijckx GJ, van Soolingen D, Aarnoutse RE, van der Werf TS.

Clin Infect Dis. 2009 Oct 1;49(7):1080-2. doi: 10.1086/605576.

PMID:
19712035
40.

Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia.

Daniels JM, Vonk-Noordegraaf A, Janssen JJ, Postmus PE, van Altena R.

Eur Respir J. 2009 Mar;33(3):670-2. doi: 10.1183/09031936.00025408.

41.

[Practice guideline prevention, diagnosis and treatment of tuberculosis in patients with an HIV infection].

van Leth F, Gebhart AC, van Altena R, Rijkeboer AA, Reusken AM, van Gerven PJ; Werkgroup TB-HIV van de Commissie voor Praktische Tuberculosebestrijding.

Ned Tijdschr Geneeskd. 2009;153:A1225. Dutch.

PMID:
20482917
42.

Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects.

Hasenbosch RE, Alffenaar JW, Koopmans SA, Kosterink JG, van der Werf TS, van Altena R.

Int J Tuberc Lung Dis. 2008 Aug;12(8):967-71.

PMID:
18647459
43.

Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.

Alffenaar JW, de Vries PM, Luijckx GJ, van Soolingen D, van der Werf TS, van Altena R.

Antimicrob Agents Chemother. 2008 Jun;52(6):2293-5. doi: 10.1128/AAC.01637-07. Epub 2008 Mar 24. No abstract available.

44.

Tuberculous peritonitis during infliximab therapy.

Verhave JC, van Altena R, Wijnands MJ, Roerdink HT.

Neth J Med. 2008 Feb;66(2):77-80.

45.

[Underdiagnosis of HIV in patients with tuberculosis].

van Altena R, van der Werf TS.

Ned Tijdschr Geneeskd. 2007 Dec 1;151(48):2652-4. Dutch.

PMID:
18179080
46.

Indications for percutaneous endoscopic gastrostomy in complex tuberculosis patients.

Warmelink G, Poels BJ, van Altena R, Peters FT.

Int J Tuberc Lung Dis. 2007 Jan;11(1):85-90.

PMID:
17217135
47.

Risk factors of acute hepatic failure during antituberculosis treatment: two cases and literature review.

Smink F, van Hoek B, Ringers J, van Altena R, Arend SM.

Neth J Med. 2006 Nov;64(10):377-84. Review.

48.

Prediction of deformity in spinal tuberculosis.

Jutte P, Wuite S, The B, van Altena R, Veldhuizen A.

Clin Orthop Relat Res. 2007 Feb;455:196-201.

PMID:
17091018
49.

Mycobacterium avium intracellulare otomastoiditis: case report and literature review.

Muller B, Kemper J, Hartwig NG, Mooi-Kokenberg EA, van Altena R, Versteegh FG.

Eur J Clin Microbiol Infect Dis. 2006 Nov;25(11):723-7. Review.

PMID:
17061096
50.

6-month treatment for bone tuberculosis.

van Loenhout-Rooyackers JH, Jutte PC, van Altena R.

Int J Tuberc Lung Dis. 2006 Sep;10(9):1063; author reply 1063-4. No abstract available.

PMID:
16964803

Supplemental Content

Loading ...
Support Center